News

Enlarge image

BusinessFrance

Ipsen nets US$50m for OBI-1

25.01.2013 - Ipsen and bankrupt Inspiration Biopharmaceuticals have inked a US$185m Asset Purchase Agreement with Baxter giving it the global rights to OBN-1.

Under the terms of the agreement, Baxter will acquire the worldwide rights to the recombinant porcine factor VIII (rpFVIII) for congenital and acquired haemophilia A, and Ipsen’s industrial facility in Milford, US. The Asset Purchase Agreement (APA) was filed on 23 January 2013, with the US Federal Bankruptcy Court in Boston (MA). The sale is a result of a joint marketing and sale process pursued by Ipsen and Inspiration shortly after Inspiration filed for protection. Ipsen has been providing Inspiration with Debtor-in-Possession financing for an amount of up to $18.3m in order to permit the sale process to proceed.

Baxter will pay $50m upfront, up to $135m in potential additional milestones as well as tiered net sales payments ranging from 12.5% to 17.5% of OBI-1 annual net sales.
The APA is subject to certain closing conditions, including Bankruptcy Court and regulatory approvals. Ipsen has agreed to extend the Debtor-in-Possession (DIB) financing to Inspiration for a period of 45 days

The sale process for IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with haemophilia B is separate and in the final bidding stage. As Inspiration’s only senior secured creditor and as the owner of non-Inspiration assets that will be included in the sale of both OBI-1 and IB1001, Ipsen will receive approximately 60% of the upfront payments. Over and above these upfront amounts, Ipsen will receive 80% of all payments up to a present value of $304m and 50% of all proceeds thereafter.

On the basis of available information, the share of upfront payment to be received by Ipsen should mainly cover the total amount of DIP financing provided to Inspiration. The remaining portion of proceeds is contingent on OBI-1’s approval. As a consequence, the Group, as of 31 December 2012, may impair haemophilia related assets for a total amount of around €100m after tax.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/ipsen-nets-us50m-for-obi-1.html

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK6.58%
  • RENEURON (UK)2.88 GBP4.73%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)11.56 USD-7.52%
  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%

TOP

  • DIAMYD MEDICAL -B- (S)6.90 SEK59.7%
  • NORDIC NANOVECTOR (N)34.00 NOK39.3%
  • KARO BIO (S)42.00 SEK36.4%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-25.4%
  • MOLOGEN (D)1.78 EUR-22.6%
  • WILEX (D)1.47 EUR-15.0%

TOP

  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%
  • GENMAB (DK)1094.00 DKK79.3%

FLOP

  • BB BIOTECH (D)44.29 EUR-83.5%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)92.00 GBP-72.0%

No liability assumed, Date: 26.08.2016